Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

NCT02168491 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG: Lixisenatide
DRUG: Insulin glargine

Sponsor

Medical University of Vienna